Automate Your Wheel Strategy on SMMT
With Tiblio's Option Bot, you can configure your own wheel strategy including SMMT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SMMT
- Rev/Share 0.0
- Book/Share 0.3494
- PB 63.4019
- Debt/Equity 0.0214
- CurrentRatio 5.1262
- ROIC -2.8456
- MktCap 16453528165.0
- FreeCF/Share -0.2793
- PFCF -79.3415
- PE -22.0472
- Debt/Assets 0.0171
- DivYield 0
- ROE -2.0863
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SMMT | Barclays | -- | Underweight | -- | $13 | Sept. 17, 2025 |
| Initiation | SMMT | Guggenheim | -- | Buy | -- | $40 | Sept. 4, 2025 |
| Initiation | SMMT | Piper Sandler | -- | Neutral | -- | $21 | Aug. 19, 2025 |
| Initiation | SMMT | UBS | -- | Buy | -- | $30 | July 1, 2025 |
| Initiation | SMMT | Leerink Partners | -- | Underperform | -- | $12 | June 11, 2025 |
| Upgrade | SMMT | Citigroup | Neutral | Buy | $23 | $35 | March 26, 2025 |
| Initiation | SMMT | Cantor Fitzgerald | -- | Overweight | -- | -- | March 21, 2025 |
| Initiation | SMMT | Evercore ISI | -- | Outperform | -- | $30 | March 12, 2025 |
| Initiation | SMMT | Goldman | -- | Buy | -- | $42 | Feb. 28, 2025 |
| Initiation | SMMT | Truist | -- | Buy | -- | $35 | Jan. 8, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT).
Read More
Ten Bull Market 10-Baggers
Published: September 22, 2025 by: Seeking Alpha
Sentiment: Positive
While broad market performance has been robust, one striking aspect of this cycle has been the extraordinary gains in a handful of individual equities. Ten stocks in the large-cap Russell 1,000 have now advanced more than 1,000% since the start of this period. We take a look at each of these names to provide insight into the breadth of forces powering this bull market beyond the headline indices.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: September 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Summit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.
Read More
Top 3 Health Care Stocks You'll Regret Missing In Q3
Published: September 09, 2025 by: Benzinga
Sentiment: Positive
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Read More
Summit Therapeutics (SMMT) WCLC Update Call (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Summit Therapeutics (NASDAQ:SMMT ) WCLC Update Conference Call September 08, 2025 08:00 AM Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West - Vice President of Clinical Development Manmeet Soni - COO, CFO & Director Urte Gayko - Chief Regulatory, Quality & Pharmacovigilance Officer Robert Duggan - Co-CEO & Executive Chairman Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Mohit …
Read More
Summit Therapeutics shares fall as lung cancer trial results disappoint
Published: September 08, 2025 by: Proactive Investors
Sentiment: Negative
Summit Therapeutics PLC (NASDAQ:SMMT) shares dropped sharply on Monday following the release of mixed results from its Phase III HARMONi trial of ivonescimab, a potential lung cancer therapy. The stock fell 23.4% to about $20 in the early afternoon.
Read More
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Read More
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
Read More
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Read More
2 Soaring Stocks With More Upside Potential to Buy and Hold
Published: July 04, 2025 by: The Motley Fool
Sentiment: Positive
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends.
Read More
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: July 02, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Summit Therapeutics (SMMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
Summit Therapeutics: Market Overreaction Creates Opportunity
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
Summit's ivonescimab showed a 48% reduction in disease progression risk in EGFR-mutant lung cancer — a best-in-class result in a tough-to-treat population. Overall survival data is trending positive but has not yet reached statistical significance; further follow-up may tip the balance. The recent stock sell-off reflects regulatory uncertainty rather than drug failure, creating a potential buying opportunity for long-term investors.
Read More
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Negative
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
Read More
Is SMMT Stock A Buy After Its Recent Plunge?
Published: June 02, 2025 by: Forbes
Sentiment: Negative
Summit Therapeutics (NASDAQ: SMMT) experienced a significant 30% decrease in its stock on Friday, May 30th, closing at $18. This sudden decline came even though the stock had doubled within the past year, driven by favorable updates regarding its lung cancer medication, ivonescimab.
Read More
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Published: June 02, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Summit Therapeutics (SMMT -30.39%) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down.
Read More
Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Negative
PFS in Phase 3 HARMONi study, using ivonescimab + chemotherapy to treat patients with EGFR 2nd-line NSCLC, was met with statistical significance, but OS was not. OS data not being met in a statistically significant manner puts doubt on company's ability to file a BLA of ivonescimab for the treatment of patients with EGFR 2nd-line NSCLC. The global non-small cell lung cancer therapeutics market is expected to reach $37.49 billion by 2035.
Read More
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.
Published: May 30, 2025 by: Barrons
Sentiment: Positive
The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese cancer immunotherapies in western countries?
Read More
About Summit Therapeutics Inc. (SMMT)
- IPO Date 2015-03-05
- Website https://www.summittxinc.com
- Industry Biotechnology
- CEO Robert W. Duggan
- Employees 159